For athletes with diabetes, continuous glucose monitors are game-changers, helping them avoid dangerous blood sugar crashes ...

Monitoring of the body’s blood sugar is essential to the treatment of diabetes. But getting effective glucose readings has ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

This innovative CBGM system, designed for continuous, accurate glucose monitoring over three years without any on-body external component, offers a more convenient and less intrusive alternative ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense ® 365 CGM system. Eversense 365 is the ...

This study represents the first real-time, continuous blood glucose monitor (CBGM ... While neither the study nor prototype system was designed to evaluate sensor accuracy, the system performed ...